376 related articles for article (PubMed ID: 23889554)
1. Use of the 13-valent pneumococcal conjugate vaccine in children and adolescents aged 6 - 17 years.
Mitchell R; Trück J; Pollard AJ
Expert Opin Biol Ther; 2013 Oct; 13(10):1451-65. PubMed ID: 23889554
[TBL] [Abstract][Full Text] [Related]
2. The future of pneumococcal disease prevention.
Rodgers GL; Klugman KP
Vaccine; 2011 Sep; 29 Suppl 3():C43-8. PubMed ID: 21896352
[TBL] [Abstract][Full Text] [Related]
3. Impact of conjugate pneumococcal vaccines on the changing epidemiology of pneumococcal infections.
Zangeneh TT; Baracco G; Al-Tawfiq JA
Expert Rev Vaccines; 2011 Mar; 10(3):345-53. PubMed ID: 21434802
[TBL] [Abstract][Full Text] [Related]
4. Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults.
Durando P; Faust SN; Fletcher M; Krizova P; Torres A; Welte T
Clin Microbiol Infect; 2013 Oct; 19 Suppl 1():1-9. PubMed ID: 24083785
[TBL] [Abstract][Full Text] [Related]
5. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
Nuorti JP; Whitney CG;
MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868
[TBL] [Abstract][Full Text] [Related]
6. Review on the immunogenicity and safety of PCV-13 in infants and toddlers.
Nunes MC; Madhi SA
Expert Rev Vaccines; 2011 Jul; 10(7):951-80. PubMed ID: 21806394
[TBL] [Abstract][Full Text] [Related]
7. Pneumococcal conjugated vaccine: PHiD-CV.
Dinleyici EC; Yargic ZA
Expert Rev Anti Infect Ther; 2009 Nov; 7(9):1063-74. PubMed ID: 19883326
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of a 7-valent pneumococcal conjugate vaccine (PCV7) and impact on carriage in Venezuelan children at risk of invasive pneumococcal diseases.
Rivera-Olivero IA; Del Nogal B; Fuentes M; Cortez R; Bogaert D; Hermans PW; Waard JH
Vaccine; 2014 Jun; 32(31):4006-11. PubMed ID: 24837505
[TBL] [Abstract][Full Text] [Related]
9. Anticapsular serum antibody concentration and protection against pneumococcal colonization among children vaccinated with 7-valent pneumococcal conjugate vaccine.
Millar EV; O'Brien KL; Bronsdon MA; Madore D; Hackell JG; Reid R; Santosham M
Clin Infect Dis; 2007 May; 44(9):1173-9. PubMed ID: 17407035
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
[TBL] [Abstract][Full Text] [Related]
11. The effect of pneumococcal conjugate vaccines on the incidence of invasive pneumococcal disease caused by ten non-vaccine serotypes in Denmark.
Slotved HC; Dalby T; Hoffmann S
Vaccine; 2016 Feb; 34(6):769-74. PubMed ID: 26772630
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity, safety and reactogenicity of the pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in 2-17-year-old children with asplenia or splenic dysfunction: A phase 3 study.
Szenborn L; Osipova IV; Czajka H; Kharit SM; Jackowska T; François N; Habib MA; Borys D
Vaccine; 2017 Sep; 35(40):5331-5338. PubMed ID: 28866290
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology of invasive pneumococcal disease in the pre-conjugate vaccine era: South Africa, 2003-2008.
von Gottberg A; Cohen C; de Gouveia L; Meiring S; Quan V; Whitelaw A; Crowther-Gibson P; Madhi SA; Whitney CG; Klugman KP
Vaccine; 2013 Aug; 31(38):4200-8. PubMed ID: 23684826
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada.
Vanderkooi OG; Scheifele DW; Girgenti D; Halperin SA; Patterson SD; Gruber WC; Emini EA; Scott DA; Kellner JD;
Pediatr Infect Dis J; 2012 Jan; 31(1):72-7. PubMed ID: 21960186
[TBL] [Abstract][Full Text] [Related]
15. The immunogenicity and safety of pneumococcal conjugate vaccine in human immunodeficiency virus-infected Thai children.
Thanee C; Pancharoen C; Likitnukul S; Luangwedchakarn V; Umrod P; Phasomsap C; Apornpong T; Chuanchareon T; Butterworth O; Puthanakit T
Vaccine; 2011 Aug; 29(35):5886-91. PubMed ID: 21729732
[TBL] [Abstract][Full Text] [Related]
16. The worldwide impact of the seven-valent pneumococcal conjugate vaccine.
Fitzwater SP; Chandran A; Santosham M; Johnson HL
Pediatr Infect Dis J; 2012 May; 31(5):501-8. PubMed ID: 22327872
[TBL] [Abstract][Full Text] [Related]
17. Impact of infant pneumococcal vaccination on invasive pneumococcal diseases in France, 2001-2006.
Lepoutre A; Varon E; Georges S; Gutmann L; Lévy-Bruhl D
Euro Surveill; 2008 Aug; 13(35):. PubMed ID: 18761883
[TBL] [Abstract][Full Text] [Related]
18. Invasive pneumococcal diseases in children in Hokkaido, Japan from April 2000, to March 2015.
Sakata H
J Infect Chemother; 2016 Jan; 22(1):24-6. PubMed ID: 26603480
[TBL] [Abstract][Full Text] [Related]
19. Induction of immunologic memory following primary vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine in infants.
Knuf M; Pankow-Culot H; Grunert D; Rapp M; Panzer F; Köllges R; Fanic A; Habib A; Borys D; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2012 Jan; 31(1):e31-6. PubMed ID: 21909049
[TBL] [Abstract][Full Text] [Related]
20. Effect of reduced-dose schedules with 7-valent pneumococcal conjugate vaccine on nasopharyngeal pneumococcal carriage in children: a randomized controlled trial.
van Gils EJ; Veenhoven RH; Hak E; Rodenburg GD; Bogaert D; Ijzerman EP; Bruin JP; van Alphen L; Sanders EA
JAMA; 2009 Jul; 302(2):159-67. PubMed ID: 19584345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
